|Bid||1.33 x 1000|
|Ask||1.34 x 800|
|Day's Range||1.31 - 1.35|
|52 Week Range||1.11 - 2.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 18, 2017 - Oct 23, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
WALTHAM, Mass., Sept. 20, 2018-- NeuroMetrix, Inc., reported that its President and CEO, Dr. Shai N. Gozani, yesterday participated in a discussion of the opioid crisis and the Company’ s Quell ® Wearable ...
LAS VEGAS, Sept. 4, 2018 /PRNewswire/ -- Tomorrow at PAINWeek 2018, NeuroMetrix Inc. (NURO), will unveil its latest breakthrough for the treatment of chronic pain. With economic costs estimated to be $635 billion per year, chronic pain is one of the most complex conditions for care providers and patients to manage, making it ripe for innovation. An estimated 100 million Americans are living with some form of chronic pain, and with the rise of the opioid epidemic, are increasingly searching for new, drug-free treatment methods.
NeuroMetrix, Inc. (NURO) today reported that it will be both exhibiting and sponsoring a diabetic neuropathy symposium at the 28th Annual Meeting of NEURODIAB held in Rome, Italy September 4-7. Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
WALTHAM, Mass., Aug. 28, 2018-- NeuroMetrix, Inc., today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference to be held in Las Vegas, NV, September ...
WALTHAM, Mass., Aug. 27, 2018-- NeuroMetrix, Inc. reported that the time previously announced for its presentation at the H.C.Wainwright 20 th Annual Global Investment Conference has been shifted to 10:00 ...
NeuroMetrix, Inc. (NURO) today announced it will be a presenting company at the 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4 - 6, 2018, at The St. Regis New York in New York City. Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. The NeuroMetrix presentation is scheduled for Thursday, September 6, 2018 at 4:40 PM Eastern time. NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes.
NeuroMetrix, Inc. (NURO), today reported that it had achieved the second development milestone under its strategic collaboration with GSK Consumer Healthcare. A milestone payment of $3.8 Million was made by GSK. In addition, NeuroMetrix and GSK will co-fund Quell technology development for an initial two-year period starting in 2019 with extensions by mutual agreement.
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free earnings report on Intuitive Surgical, Inc. (NASDAQ: ISRG), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ISRG. The Company reported its second quarter fiscal 2018 operating and financial results on July 19, 2018. Additionally, the Company provided its guidance for FY18.
WALTHAM, Mass., July 19, 2018-- NeuroMetrix, Inc., today reported financial and business highlights for the quarter ended June 30, 2018.. The Company develops and markets novel therapies, based on neurostimulation ...
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 19, 2018 at 8:00 AM Eastern Time. To ...
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2018 second quarter financial results before the opening of the market on Thursday, July 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern Time on July 19, 2018 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7894528.
WALTHAM, Mass., July 05, 2018-- NeuroMetrix, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,004,445. The patent covers novel technology that enhances DPNCheck ...
NeuroMetrix, Inc. (NURO) in conjunction with its public relations firm, InkHouse, received two prestigious awards at the 50th annual Bell Ringer Awards gala on Wednesday, June 13th hosted by The Publicity Club of New England, the region’s leading communications trade organization. Quell® by NeuroMetrix, in partnership with InkHouse, won the Gold Award for the campaign launched in 2017: “Moving Beyond Opioids: How Technological Innovations Can Impact Chronic Pain,” addressing drug free alternatives for chronic pain. Also, NeuroMetrix and InkHouse received a Silver Award in the owned media category for the LivingQuell blog.
NeuroMetrix, Inc. (NURO), today reported publication of three new clinical studies on DPNCheck®, a point-of-care device that provides accurate and cost-effective screening, diagnosis, and monitoring of diabetic peripheral neuropathy (DPN). Journal of Diabetes Investigation - Difference in normal limit values of nerve conduction parameters between Westerners and Japanese people might need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device. Binns-Hall’s study of 236 patients assessed the feasibility of assessing diabetic patients for neuropathy during routine diabetic eye exams in community clinics.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a multi-year extraction agreement with Canopy Growth that sent shares of Neptune Technologies flying higher on Tuesday. Shares of NeuroMetrix also scored ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Neurometrix Inc (NASDAQ: NURO ) stock was trading ...
Shai Gozani took the reins as CEO of NeuroMetrix Inc’s (NASDAQ:NURO) and grew market cap to US$9.86M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
For NeuroMetrix Inc’s (NASDAQ:NURO) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...
LONDON, UK / ACCESSWIRE / May 11, 2018/ If you want a free Stock Review on EKSO sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), Hill-Rom Holdings Inc. (NYSE: HRC), and NeuroMetrix Inc. (NASDAQ: NURO). Companies in the Medical Instruments and Supplies Manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.